

Ibuprofen

FORM Oral suspension containing 100mg in 5ml

INDICATION Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.

DOSE RANGE

AGE	DOSE	FREQUENCY	ROUTE
Preterm neonate < 34 weeks gestation	10mg/kg	LOADING DOSE 1 dose only followed at 24 hour intervals by 24hours after loading dose	Oral/NG
	5mg/kg	2nd and 3rd doses given at 24 hour intervals*	Oral/NG

* If the ductus arteriosus does not close 48 hours after the last dose or if it reopens, a second course of 3 doses, as above, may be given. If the condition is unchanged after the second course of therapy, surgery of the patent ductus arteriosus may then be necessary. Alternatively, if duct remains open 24 hours after third dose, a fourth and fifth dose of 5mg/kg may be given at 24 hour intervals

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION

Contraindications for 1st dose

- Known renal anomaly
- Anuria
- Creatinine ≥ 100 and rising or creatinine > 120 mmol/l (no need to check if giving as prophylaxis)
- Known GIT anomaly or bleeding
- Active or suspected NEC
- Platelets $< 100 \times 10^9/l$ (consider transfusion and then treating)
- Severe coagulopathy (only check clotting if clinical concern).
- Active bleeding (but not intraventricular/ periventricular haemorrhage or pulmonary haemorrhage)
- Associated dexamethasone treatment

Contraindications to subsequent doses:

- **As above with the following exceptions**
- Creatinine ≥ 150 mmol/l (check before 3rd dose or when clinically indicated)
- Urine output < 1 mL/kg/h (recommence if recovers and creatinine acceptable)
- Platelet count $< 50 \times 10^9/l$ (before 3rd dose or when clinically indicated). Consider correcting and treating PDA

LICENSED STATUS Unlicensed use.

LINKS [BNF for Children:](#) / [Electronic Medicines Compendium](#)

West of Scotland ORAL/ OTHER ROUTE Drug Monographs

APPLICABLE POLICIES

[West of Scotland Neonatal Guidelines:](#)

Consult local policy if applicable

Document Number:	002	Supersedes:	001
Prepared by:	Peter Mulholland	Checked by	WoS Neonatal Pharmacists
Date prepared	January 2017	Date updated	August 2021
Updated by	Peter Mulholland	Review Date	August 2024

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications.
This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.